cyrilzakka/clinical-trials huggingface dataset:
Biomechanical and Viscoelastic Properties of Plantar Fascia in Pregnant Women

Pelvic girdle pain is frequently experienced in pregnant women and the mechanism of pelvic girdle pain is not known exactly. The aim of this study is to investigate the effect of biomechanical and viscoelastic properties of plantar fascia on pelvic girdle pain in pregnant women.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant women in the 2nd or 3rd trimester of pregnancy with pelvic girdle pain
* Pregnant women in the 2nd or 3rd trimester of pregnancy without pelvic girdle pain
* First pregnancy
* 20-40 years old
* Healthy woman without pregnancy

Exclusion Criteria:

* Participant having any kind of connective tissue disease
* Presence of orthopedic or neurological problems in the lower extremities that may cause musculoskeletal disorder and biomechanical alignment deviations
* Presence of foot pain that started before pregnancy and lasts for more than 3 months
* Presence of lumbar-pelvic pain that started before pregnancy and lasts for more than 3 months
* Have had 2 or more births
* Presence of multiple pregnancy (twins, triplets etc)
* Presence of ankle-ankle fracture and operation history in the last 6 months
A Brief Behavioral Sleep Intervention for Depression Among Military Veterans

This study investigates the impact of brief behavioral insomnia treatment on depressive symptoms among military veterans.


Eligibility Criteria:
* Age 18 or older
* Veteran
* Insomnia Symptoms
* Depression
Use of Different Electrophysical Agents in Cervical Region Flexibility Training of Healthy Individuals

60 healthy participants with right / left upper trapezoidal shortness based on volunteering will be included in the study. Participants were randomly divided into 4 groups; Traction and stretching exercises to group 1 (n = 15), laser therapy and stretching exercise to group 2 (n = 15), hot pack and stretching exercises to group 3 (n = 15), and group 4 (control group) only stretching exercises will be applied.

Healthy individuals without any cervical region pathology will be included in the study. Exclusion criterias are pregnancy or cancer, hypertension that cannot be controlled, having neurological symptoms, previous spinal surgery.

Demographic information of the participants will be recorded; cervical joint range of motion (CROM device), muscle shortness (acromion-earlobe and occiput-wall distance measurement), deep cervical flexor muscle strength (Stabilizer Pressure Biofeedback), cervical performance level (Cervical Performance Tests), muscle spasm (Palpable Muscle Spasm Scoring) will be evaluated. Cervical joint range of motion and muscle shortening will be repeated before and after each session, but other parameters will only be repeated at the beginning and the end.

Eligibility Criteria:
Inclusion Criteria:

-Healthy individuals without any cervical region pathology

Exclusion Criteria:

* Pregnancy and cancer
* Uncontrolled hypertension
* Presence of neurological symptoms
* Spinal surgery history
The Long-lasting Effects of Repetitive Neck Muscle Vibrations on Postural Disturbances in Standing Position in Chronic Stroke Patients

One of the causes of disability in patients suffering from a stroke is postural imbalance. Sensory stimulation improves the postural symmetry of the subject transitorily and they are thought to have an effect on the spatial frame of reference through a sensory recalibration. Studies have shown that sensory stimulation by vibration of neck muscles have an immediate effect on static balance and when walking. The objective of this preliminary study is to test the long-lasting effects of repetitive neck muscle vibrations on postural disturbances in standing position and on spatial frame reference in chronic patients.

The hypothesis of this study is that the proprioceptive repeated stimulation by vibration of neck muscles in the long term improved postural asymmetry in connection with the egocentric representation of body disorders.

The effect of vibration simultaneously on improving postural asymmetry and on improving markers of the perception of the body in space (LBA, SSA, Subjective Visual Vertical (SVV), Rod and frame) will be assessed.

Eligibility Criteria:
Inclusion Criteria:

* Adult (age ≥ 18 years) under 80 years,
* Right or left unilateral supratentorial ischemic or hemorrhagic lesion
* The first symptomatic episode
* Stroke

  * older than 12 months
  * with or without hemianopsia
  * with or without visuospatial hemineglect
* Standing balance ≥ 30 sec unaided
* Percentage of weight bearing asymmetry on the hemiplegic lower limb (on a force platform)
* Written informed consent of the patient or a member of his entourage (in the case of patients with motor difficulties)

Exclusion Criteria:

* Orthopaedic, rheumatologic, neurologic, vestibular or visual disorders affecting the distribution of the centre of pressure while standing on the force platform
* Visual disorder that does not allow assessment of the spatial frame of reference test
* Difficulty with understanding protocol procedures
Effects of Vitamin D on Moderate to Severe Periodontitis

The object of the study was to evaluate the direct effect of high dose vitamin D supplementation on chronic periodontitis, and suggest the recommended dose for clinic use.

Periodontitis is a chronic inflammatory disease characterized by periodontal tissues inflammation and alveolar bone loss. Vitamin D is involved in stimulating osteoblasts to enable normal bone growth and preservation, also the regulation of cellular proliferation, differentiation, innate immune response and anti-inflammatory effect.Previous studies have reported the association of vitamin D levels and gingivitis and periodontitis. This study was designed as a randomized controlled trial to evaluate the effect of vitamin D supplementation on chronic periodontitis.

The study was divided into two phases. Recruitment including baseline clinical measurements was obtained and standard periodontal treatments were performed in Phase One. The randomization and intervention of vitamin D were performed in Phase Two. The 323 subjects were randomly divided into 3 groups (n=105,110,108) to receive a supplement kit containing 90 capsules of 2000 IU vitamin D, 1000 IU vitamin D, or placebo capsule for 3 months. After intervention, all the subjects were followed up after 3 months and received standard periodontal examination, including attachment loss (AL), probing depth (PD), bleeding index (BI), and panoramic radiographs were taken to evaluate alveolar crest height (ACH).

Eligibility Criteria:
Inclusion Criteria:

1. Age from 30 years old to 70 years old
2. More than 20 teeth remaining in the mouth
3. Clinical diagnosis of moderate to severe periodontitis
4. Not receiving periodontal treatment within 6 months
5. Not taking antibiotic drugs within 3 months.

Exclusion Criteria:

1. Diabetes, thyroid and parathyroid endocrine associated diseases
2. Severe systemic diseases, such as cancer
3. Taking vitamin D and / or calcium drugs during observation
4. Taking aspirin, non-steroidal anti-inflammatory drugs, and steroids
5. Pregnant or prepare to pregnant within one year
6. Have been suffering from hypercalcemia, malabsorption syndrome.
Cognitive Enhancement on Working Memory in Patients With Schizophrenia

The investigators plan to investigate the effect of enhancement on working memory (WM) in patients of chronic schizophrenia and determine the predictive factors of effective treatment.

Schizophrenia is a chronic and disabling disease with a prevalence of 0.5%\~1.5% in the general population. It's estimated 98% of patients with schizophrenia exhibit variable degrees of cognitive deficits which have been well established to be predictive of patient functioning. A number of treatments had been developed for cognitive enhancement in patients with schizophrenia, nevertheless none of them showed satisfying results.

Transcranial direct current stimulation (tDCS) is a safe and convenient treatment which has showed some evidence of beneficial effects on working memory (WM) in both healthy and neuropsychiatric populations. However, studies of tDCS for cognitive enhancement in patients with schizophrenia are still quiet limited. The results of our previous studies in healthy participants and patients with diabetic polyneuropathy suggest that the anodal tDCS over right dorsolateral prefrontal cortex (DLPFC) improved spatial WM capacity, particularly when task difficulty demands more complex mental manipulations and for the low-performing patients in baseline assessments. Thus, we hypothesize that in the baseline the more severe the patients' cognitive deficit are, the greater their WM capacity improvement would be after applying the anodal Tdcs over right DLPFC.

The investigators plan to recruit 40 patients with chronic schizophrenia. First, the investigators will collect baseline characteristics including disease severity, cognitive deficits and brain connectivity. Then the investigators will adopt a sham-active crossover design for tDCS treatment with the order of the two sessions (sham and active) counterbalanced across participants. The investigators will perform pre- tDCS and post- tDCS assessments of their spatial WM and verbal WM as well as statistical analyses to see if the effect of cognitive enhancement reaches a significant level. In addition, the investigators will explore the possible predictive indicators of effective treatment.

Eligibility Criteria:
Inclusion criteria

1. Inform consent acquired
2. Age 20 to 50
3. Right-handed
4. Patients with schizophrenia diagnosed according to DSM-5 criteria

Exclusion criteria

1. Participants who are pregnant or breastfeeding
2. Participants who have metal implants
3. Participants who have alcohol/substance use disorder or received electro-convulsive therapy within the past 6 months.
4. Participants who have history of head injury with loss of consciousness
5. Participants who have history of brain lesions, infection, or epilepsy
6. Skin lesions on the electrodes placed
7. Cancer patients
8. Patients with high fever
9. Patients with significant sensory loss
Effects Of Post Isometric Relaxation And Post Facilitation Stretching On ROM, Pain And Functional Limitations

Study Design: Randomized Controlled Trial treatment techniques: post isometric relaxation and post facilitation stretching technique sample size: 35 in each group single blinded Before giving either treatment to each group, baseline data will be collected from each participant and then after 4th week of treatment.

To compare the effects of post isometric relaxation and post facilitation stretching on Rom, pain and functional disability in patients with erector spinae tightness.Study Setting: Bahria International Hospital, Lahore Data will be analyzed using SPSS version 26.The quantitative variables like range of motion will be presented in the form of mean ±SD and qualitative variables like pain and functional disability will be presented in the form of frequency and percentage.

Eligibility Criteria:
Inclusion Criteria:

* • Pain in lower back for atleast 4 weeks but less than 1 year.

  * Pain relieved by rest.
  * Decreased flexion, extension and lateral flexion of lumbar spine.
  * Individuals having no signs of nerve root irritation (dermatomal pain and paresthesia) and nerve root compression (dermatomal sensory loss, myotomal weakness, loss of reflex)
  * Age group: 30 - 45 years
  * Both male and female

Exclusion Criteria:

* Individuals having other lumbar pathologies like disc problems, ligamentous strains, sciatica etc
* Individuals having any inflammation and malignancy.
* Pregnancy
* Individuals having recent trauma, fracture, or surgery
Randomized Controlled Trial Comparing Drains Usage Vs Without Drains After Thyroid Surgery

The aim of this study is to compare patients who used drain to patients who did not use drain post-thyroidectomy regarding the short-term outcomes .


Eligibility Criteria:
Inclusion Criteria:

* (1) Male or female patients undergoing thyroidectomy (2) Patients with ages: from 18 to 60 years old. (3) Patients with normal thyroid function tests (4) Patients who are fit for general-anesthesia.

Exclusion Criteria:

* (1) Patients with bleeding diathesis and those on anticoagulants. (2) Patients with thyrotoxicosis (uncontrolled) (3) Patients those requiring neck L.N dissection. (4) Patients with previous neck surgeries. (5) Patients with severe comorbid conditions with high risk for general anesthesia.
5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris

12-week study to compare the efficacy and safety of a course of a twice daily treatment with APS in the form of a lotion to its vehicle for the treatment of acne.


Eligibility Criteria:
Inclusion Criteria:

* Subject has read, understood, and signed appropriate informed consent, photo consent, and HIPAA consent in their own language.
* Subject has visible mild to severe acne, as assessed by the investigator.
* Subject will be available and willing to return for follow-up visits.
* Subject agrees not to use any other acne treatment products during the study.
* Subject is otherwise healthy, non-febrile, and is not suffering from an infection likely to require antibiotic therapy during the study period.
* Subject or guardian must be able to understand the new HIPAA regulations and sign the HIPAA form.
* Subject is between the ages of 18 and 39.
* Subject agrees and understands that APS or its vehicle is to be applied to the subject twice daily for 12 weeks; no other topical or systemic medication affecting the course of acne and/or evaluability is to be used during the study.
* Subject agrees to use only the cleanser, moisturizer with sunscreen, and treatment provided by the study site for the duration of the study.
* Subject understands and agrees that he/she can not be treated with a systemic antibiotic for acne during the study.
* Subject agrees he/she will not use an acne topical treatment for two weeks prior to Day 0.

Exclusion Criteria:

* Subject or guardian has not signed informed consent, photo consent or HIPAA form.
* Subject is suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment which in the opinion of the investigator could influence the results of the study.
* Subject is pregnant or lactating.
* Subject is suffering from an abnormal skin condition not usually associated with acne.
* Subject will not be available for follow-up visits.
* Subject has been previously enrolled in any clinical study in which treatment was received within the past 30 days.
* Subjects without comedones, papules, pustules, or nodules.
* Subject has a history of hypersensitivity to any other ingredients of the study lotion.
* Subject has a history of anaphylaxis.
* Subject is not able to avoid excessive sun exposure.
Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease

Based on Parkinson's disease (PD)/vitamin B12 deficiency symptom overlap and PD patients' propensity to avoid protein (the dietary source of vitamin B12), this study proposes to prospectively investigate the vitamin B12 status of PD patients over time. In addition, this study will provide critical pilot data evaluating the efficacy of treating those patients considered to have below-normal vitamin B12 levels in serum. Further, it will also explore the concept that supplementing PD patients having "low-normal" vitamin B12 levels with vitamin B12 improves either the non-motor PD symptoms or homocysteine levels in PD patients receiving levodopa.

Study Hypotheses:

1. Serum cobalamin (B12) concentrations in patients with Parkinson's disease (PD) are significantly lower than B12 concentrations in a) cohabiting spousal caregiver controls; and b) population-based, age-matched controls.
2. Supplementation with B12 in levodopa-treated PD patients with low (\<200 pg/ml) or low-normal (200-300 pg/ml) serum B12 levels is associated with significant improvement in their non-motor symptoms and reduces total plasma homocysteine concentration \[Hcy\], a known biomarker for risk of dementia and cerebrovascular disease.


Eligibility Criteria:
Inclusion Criteria:

* Patients seen in Emory Healthcare System at least once between 1/1/2002 and 05/31/2006 with idiopathic Parkinson's disease (defined as):
* \>2 of cardinal signs/symptoms of Parkinson's disease (bradykinesia, tremor, rigidity)
* \>50% improvement of symptoms when dopaminergic therapy started
* Cohabiting spousal caregivers (without Parkinson's disease) of patients enrolled in study are also eligible (but not required) to participate

  * Coexisting depression, if present, is stable
  * Normal thyroid screen (done at Screening Visit or at Emory Healthcare System within 3 months of Screening Visit)
  * Males must have normal fasting testosterone levels (done at Screening visit or within 6 months of Screening Visit)

Exclusion Criteria:

* Unstable medical conditions (terminal cancer, angina, etc) which could interfere with study assessments or put patient at risk for not completing the assessments.
* Dopaminergic-unresponsive parkinsonism (i.e., patient has suspected multiple systems atrophy (MSA), vascular or another form of parkinsonism)
* Prior history of vitamin B12 deficiency or taking vitamin B12 supplements or injections (single multivitamin supplements are not an exclusion criteria)
* Untreated testosterone or thyroid abnormality
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse.

The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.


Eligibility Criteria:
Key Inclusion Criteria:

* Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:
* Must have a confirmed diagnosis of RRMS according to McDonald criteria #1-4.
* Must have a baseline EDSS between 0.0 and 5.0, inclusive.
* Must have relapsing-remitting disease course.

Key Exclusion Criteria:

* Unless otherwise specified, candidates will be excluded from study entry if any of the following exclusion criteria exist at randomization:
* Other chronic disease of the immune system, malignancies, acute urologic, pulmonary, gastrointestinal disease.
* Pregnant or nursing women.

Note: Other protocol-defined inclusion/exclusion criteria may apply.
Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass

Research on automatic detection of ovarian mass and intelligent auxiliary diagnosis system based on multimodal ultrasound images.

Investigators aimed to develop an ultrasonic intelligent diagnosis system for ovarian mass based on multimodal ultrasound images.

Eligibility Criteria:
Inclusion Criteria:

1. During gynecological ultrasound examination, at least one patient with persistent ovarian tumor was found.
2. The patient underwent surgical treatment and the histopathological results.

Exclusion Criteria:

1. Histopathological analysis confirms non-ovarian tumor;
2. Histopathological results are inconclusive;
3. Issues with image quality: the ovarian mass is incomplete and does not show some surrounding tissues (but the mass is too large to exclude completely); the images are overly blurry, making it difficult to determine the characteristics of the ovarian mass (possible reasons include hardware quality issues with the ultrasound machine, motion blur, focusing problems, presence of intestinal gas in the patient); gain settings make it difficult to judge the characteristics of the ovarian mass (such as low contrast, excessively dark images, or saturation); the presence of artifacts affects the assessment of ultrasound characteristics of the ovarian mass and should be excluded.
HEARTPrep: A Virtually-delivered Psychosocial Intervention for Mothers Expecting a Baby With Congenital Heart Disease

Congenital heart disease (CHD) is the most common birth defect and is increasingly diagnosed prenatally. Mothers describe their prenatal experiences as highly stressful and traumatic after a diagnosis of CHD. Maternal stress during pregnancy exerts a powerful influence on birth outcomes and developmental trajectories, particularly for children in underserved populations. In partnership with diverse parent and clinician stakeholders, our team designed HEARTPrep, an innovative, virtually-delivered psychosocial intervention for mothers expecting a baby with CHD. This project will pilot HEARTPrep with mothers expecting a baby with CHD to obtain preliminary data for a larger future trial. This intervention has the potential to improve emotional wellbeing in mothers expecting a baby with CHD, thereby altering developmental trajectories for this large population of children.

Congenital heart disease (CHD) is the most common birth defect and is increasingly diagnosed prenatally. Mothers describe their prenatal experiences as highly stressful and traumatic after a diagnosis of CHD. Maternal stress during pregnancy exerts a powerful influence on birth outcomes and developmental trajectories, particularly for children in underserved populations. Targeted efforts to mitigate impacts of maternal stress for this highly vulnerable population are lacking. In partnership with diverse parent and clinician stakeholders, the investigators designed HEARTPrep, an innovative, virtually-delivered psychosocial intervention for mothers expecting a baby with CHD. HEARTPrep will be delivered through the Nemours App, an accessible tool for telehealth and patient education. The investigators aim to determine whether HEARTPrep modules produce clinically significant improvements on outcomes in mothers expecting a baby with CHD (Proof-of-Concept). This program of research has the potential to improve emotional wellbeing in mothers expecting a baby with CHD, thereby altering developmental trajectories for this large population of children.

Eligibility Criteria:
Inclusion Criteria:

* Expectant mothers carrying a fetus with congenital heart disease expected to require cardiac surgery in the first year of life
* Partners of participating expectant mothers can also participate together with the mother
* Receiving fetal cardiac care at Nemours Children's Health
* Speaks English or Spanish fluently
* Age 18 or older
* Access to a computer, tablet or mobile device with internet access

Exclusion Criteria:

-Fetus has a genetic syndrome or other comorbid condition associated with a life expectancy of less than one year
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults

There are 2 parts to this study: a single ascending dose (single dose of mRNA-6231) part and a multiple ascending dose (repeat doses of mRNA-6231) part. The main goal of this study is to evaluate the safety and tolerability of escalating doses of single and repeat subcutaneous (SC) administration of mRNA-6231. Dose levels of mRNA-6231 are planned to be investigated in a dose-escalation manner.


Eligibility Criteria:
Key Inclusion Criteria:

* Understand and agree to comply with the study procedures and provide written informed consent

Key Exclusion Criteria:

* Has received any investigational product (for example, study drug, biologic, device) within 30 days or 5 elimination half-lives, whichever is longer
* Pregnant or lactating women
* Men and women of childbearing potential without effective contraception during the study
* Has any lab abnormalities or clinically significant medical condition that could interfere with the interpretation of study results or limit the participant's enrollment